AMGN
Amgen Inc.
$378.88
▼ -1.63%
−$6.28
NASDAQ · Healthcare · Drug Manufacturers - General
· price updated 9h ago
Amgen Inc.
AMGN · NASDAQ · Healthcare · Drug Manufacturers - General · price updated 9h ago
$378.88
▼ -1.63% · −$6.28 today
AI research · $378.88
Track AMGN for continuous AI research
price position
Where AMGN sits now
52-week range
Low$269.77
High$391.29
Today $378.88
RSI (14)
57.9Neutral
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$12.0B
Total debt$57.3B
Net cash after debt$-45.3B
Valuation
What the market charges
Forward P/E
Price against expected earnings
Favorable · 14% below Sector avg · favorable
17.06x
Price / sales
Value assigned to each sales dollar
Reasonable · Between 3x and 8x sales
5.59x
Price / FCF
Price against free cash generation
Reasonable · Between 20x and 35x free cash flow
24.18x
EV / EBITDA
Operating value including debt
Reasonable · Between 12x and 22x EBITDA
16.37x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Strong · At least 15% return on capital
19.1%
ROE
Profit generated from shareholder equity
Favorable · Exceptional vs sector peers
101.3%
Debt / equity
Balance-sheet leverage
Needs attention · Among weakest in sector
6.24x
Current ratio
Short-term assets against liabilities
Reasonable · Assets still cover near-term liabilities
1.26x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How AMGN compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $207.87B | 26.8 | +9.1% | 58 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
activity
What is moving AMGN
US stock research
About Amgen Inc. (AMGN) stock
Amgen Inc. tracked in the US core universe. AMGN was -1.6% in the latest available session at $378.88. Its reported market value was $207.87B with a trailing P/E of 26.8. Latest reported revenue was $37.22B, changing +9.1% year over year, with $7.80B in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $378.88
- Day change
- -1.6%
- Market cap
- $207.87B
- P/E (TTM)
- 26.8
- Revenue growth
- +9.1%
- Industry
- Drug Manufacturers - General